PODD - Earnings call transcript Q4 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon, ladies and gentlemen. And welcome to the Insulet Corporation Fourth Quarter and Full Year 2019 Earnings Call. At this time, all participant lines are in a listen-only mode. Later, we will be a question-and-answer session. [Operator Instructions].

conference being this reminder, a call recorded. is As

hand over President, to would Relations now host, conference to like Vice I your the Deborah Corporate Communications. and Investor Gordon,

Deborah Gordon

Good quarter and year for Lauren. Thank thank call. full everyone for fourth today XXXX you you, Insulet’s joining afternoon us earnings and

Joining Chief Officer; Financial Wayde me President Executive McMillan, Executive Shacey Chief Petrovic, Officer. Vice are and and President and

year website this fourth available and of will guidance on results full the quarter release of be XXXX call website. replay our quarter our The in first our press discussing and year section and XXXX and archived the full IR also is

and to by expectations. current materially ask Before for we course in differ that call the We like explanation to refer filings of you SEC contained that a forward-looking such certain the this statements inform detailed Insulet would the of could during forward-looking our limitations statements. statements cautionary made begin, from of I please be you inherent may

also We non-GAAP EBITDA adjusted our measure, respect financial to with guidance. discuss will the

other helpful a management period investors, to operating to we transitioned what aligns believe with performance measure as it from our a as measure supplemental that of is it our have adjusted in and and as EBITDA analysts, adjusting We interested performance uses parties operating to comparative period.

be Also, unless otherwise a year-over-year on and will stated, regarding basis. changes commentary all financial percentage dollar

that, over With Shacey. call I'll turn the to

Shacey Petrovic

exciting was everyone. afternoon, an Thanks, celebrated XXXX good milestones. We of Deb, the and year. achievement many

Insulet and And of to the create several people to of and our Our lives so strategic performance of grow staying diabetes. discipline operational to evolve. which strong from mission strong a years did with true improve reflected culmination the of we foundation financial can

on progress Throughout advancing imperatives. focused in made forward. XXXX, great XXXX, our initiatives we remain our driving And we strategic

experience. excellence. deliver focused our two, and customer Three, operational drive Specifically, ensure the global one to four, innovation, expand footprint, best consumer global

just our represent diabetes of in to we tremendous Type sustainable market growth are million the ahead, requiring X Insulet This positioned confident long-term The uniquely opportunity in underserved individuals, look XX are growing we strategy insulin As and large, the global markets is is value approximately represents that execution capture. a Type we opportunity and global countries that and creation. driving X today.

We on the and over long XXXX achieve track about additional to are catalysts our excited growth financial term. our for targets,

financial detail, I over the progress. During share strategic turn our provide and highlights, overview then who I today's will financial to our and call an of XXXX share greater our results will in discuss our outlook. Wayde call, will recent

quarter by fourth million quarter Omnipod more of $X Our was results year-over-year. continuing execute growth high XXXX total our line, end for revenue Insulet. generated million driven exceeding XX% $XXX marked U.S. in closed another and XX% with guidance financial This operational exceptional and an strong product a in increase the We strong of international our both and to performance performance. drive by operations our out representing revenue than and

another new achieved global also quarter We users. record iPod of

XX% financial representing product by consistent generated XXXX. outperformance we revenue throughout $XXX full a On delivered million Omnipod line. increase, growth year revenue in a total our basis, We in XX% driven

operating to which will annual shortly. profitability improved Wayde also We speak

starting all to on with deliver now color additional I'll value out team with of and our on provide strategy, to to to intense Insulet an best execution progress of we continues drive mission it made the stakeholders. our innovation. our Our knock the park order executing focus, the in share

to the Omnipod for States, select XXXX, launch the we to introduced in products continued to and quality we our In DASH life advance easy of use, December, improve United to are completed efforts We of simple, DASH that outcomes our deliver and and European consumers. markets. in

DASH Omnipod unparalleled utilizes our phone, of on system of simplicity to ease intuitive mobile many and locked you app provide use. a know, down consumers, a As

closer able one Horizon of top With smartphones. are consumers request diabetes to launch will and from personal a being we is the to community we control with DASH get make This Omnipod the reality. the step it their their own pods

DASH, market our with be and model. is With market unique business on in only Omnipod pay-as-you no the upfront go period. we DASH lock that are disrupting cost year can the U.S. pump four insulin accessed with the no

can technology shifting lock-in period having are paradigm restrictions, without wait by easily pay end, the We large people our to upfront to and eliminating for so old their costs. having to market more access without

access providing allows we population. to business diabetes patient positioned are DASH uniquely market, address. is X Type This broader better As Omnipod serve a to the a model much result, to us which

doctors as an alternative While to they to tell increasingly their patients, willing pump Type now for less population DASH prescribe therapy they are Omnipod historically have X been daily for recommending us this injections. multiple

all of quickly platform backgrounds the Our to are and easy on minimal running and ages training, requires is up so system. and users use

the To third result, a the perspective, QX, almost in U.S. Omnipod in individuals notable into our new put As the were consecutive this users we saw being new users living quarter, pharmacy our through of Type with another percentage increase for XX% Type Omnipod X X. of diabetes.

its to who expect trend to X results our it realize This Type already that continue Omnipod confident in momentum. benefits. gain is are users many try evident we and We DASH

of than slightly momentum they to XX% which DASH of average. increase Omnipod the from we users. as and QX, an to new historical number is the In us continue encouraging growing daily market coming Omnipod access greater over our injections, saw Also total is created fuel new users Omnipod multiple have

pharmacy model access. Omnipod to benefits growth benefit as the people model category continues pay-as-you-go the way pump a line get the be the grower, in helping with with therapy. more to of in DASH And pharmacy lead of continues business the Omnipod of

be powered tubeless, controlled, progress Horizon, and several The our personal successful smartphone it wins for access by Omnipod time One, launch for a Omnipod it controlled first therapy by closed making pipeline. will resulting system. greater the designed smartphone. on ever Omnipod provide are is differentiators. of Two, We're personalized commercial and delivery in automated user's can way unparalleled market paving loop. DASH the innovation key it Horizon good three, insulin personal has

In which support completed testing filled. across fly moved country been the pivotal we participation study, our submission. spots, for incredible, remaining pre pivotal will have willing for Demand trial which FDA people to December, our and into been now with has the last

will In pivotal enrolment, fact outpatient XXX weeks, X individuals, in the total, XX study. participants our of a three completed to includes our within month sites All and years complete old. approximately ages majority

differentiator also MDI and just using pump population from include both is controlled to AID therapy, This It already is the patients individuals coming better controlled that important not participants therapy. Systems. to other and adult note our well compared another pump paediatrics or

Investigators are feedback study of We terrific. has the stage changer, that automated will been shared final stories testing, a wearing for diabetes participants excited Horizon many are our participants landscape be insulin system incredibly this Omnipod transform amazing of and and of have home at part and game as how delivery.

finally life their their adults ability tight are their Mothers of sleep maintaining the who who and through manage is improvements parties, controlled. recitals more control to well quality are Children and child can who of glucose experiencing easily night, a diabetes. pizza dance as while result through

by present of the clinical Diabetes pre American will to our June, and share was one pivotal invited investigators We study Association of a conference Horizon in ADA data principal results at our special in our session. Omnipod

later a expect to in conference it share for publication also testing this the at either later We pivotal and or data our this summer, completed be we will year.

pod. Another The keep to key Horizon's power user Omnipods design user direct does systems. need should closed on device remain period communication. on the loop as compared aspect time not the for of a its is the of to This in sensor algorithm and innovative body a CGM in Pod other the to longer allow incorporating

worked have In partner. long order to Dexcom, with a collaboration standing accomplish in close this, we

We Omnipod excited next-generation really our to to Dexcom’s recently and builds includes on announced are into integration access our launch CGM integrate an GX agreement formalizes that plans, Horizon. commercial efforts, have

partnerships living have is just to Our freedom insulin will Horizon an to diabetes. illustration of that with AID of established deliver innovative several bring and simplicity we an with people platform dependent effort one Dexcom

to our a next automated body an our insulin users trajectory million system delivery remarkable adoption generation have technologies a CGM Omnipod Abbott, sensor the diabetes. across will Abbott's very platform partner impact on This Libre exciting choice has announced patients system. provide it’s in the than sensor. more intuitive, about had can recently and together on Libre living with together broad recently power the X collaboration And Horizon to with of also think another of longstanding globe. We bring people celebrating with

with position platform will personalization complexity. diabetes simple those the our market, of X. without design, Omnipod penetrate us of sensor and We The believe Type to a including living provide global differentiators outcomes further choice

concentrated incredibly in Due have our to large we partners. shift efforts AID resources with insulin this over opportunity, maximizing development development efforts sensor toward these our programs order our prioritized to development

effectively believe Our and on our rationale much a technology move provide and with of benefits addressable X collaboration into change Dexcom We expanded larger, for is the our matter to opportunity. together this a market. priority market of rapidly a platform based more diabetes with Type pathway Abbott

driving to current with to already will Omnipod adoption. partner and winning strategy population, and deliver a to benefits approach Abbott focused consumer excited larger a are be is Dexcom to our provide off that proving innovation We to build that

a top here priority is Innovation Insulet. at

growth to We bring will and in with advancements invest to world. opportunities around help to more continue our people greater us the pipeline accelerate diabetes

our expect our XXXX in roll introduced large, position and tremendous the this end we Canada year. securing Now global footprint geographies select to markets, addressable European in to leadership our and DASH expansion. we in XXXX, progress of further made out By global Europe it markets. Omnipod turning and across We strengthening with

announced Middle the value where to Europe, demand feedback Additionally, new this that significant in received we we've and term and and specifically long five positive potential. we encouraged adopters. markets Omnipod the preferred the is see last platform DASH by expect markets early European from we year creation month new enter our we are for our East

or While we don't revenue over we we to our the steps add and to sustainable that XXXX, long expansion right meaningful taking international drive term. expect the are our confident are revenue in European growth significant

our excellence. Finally, operational global and manufacturing innovation turning to

on of challenges and the highlights First, supply importance families, impact I acknowledge we our and like the with global chain of employees global in the as redundancy. coronavirus its it and many investment organizations; to would of operations manufacturing, the all that deal

our our last year, on of not internal first we in we line so, expertise, support strengthened we scale, States. of long redundancy, the own to only May the our the valuable our doing our highly manufacture needs. In chain. rapid expertise to chain term and production In developed at and internal ability state added growth complexity expanded products and capacity of manage manufacturing supply automated are began also manufacturing capacity, supply United Possessing the art and critical

line, We our are up first X of sellable of in the second middle production manufacturing the mid-year. line line with by and starting product expected U.S. and ramping

the remain sellable with manufacturing year this on also our product next We to third United line later States track install in year.

while near is and XX% target, term, effectiveness, remain supply chain XXXX take operations. advantages manufacturing With on key which driving a headwind of we innovation on significant cost our And long our the effort. the we drive will in deliver. ramp our focus margin term to and this scope complexity It we does of that competitive the a to ramp margins have and driver reductions across gross track time this expect is lines created to our given efficiency manufacturing

Wayde. ahead, now look I'll opportunities. and remain continuing strategy our turn our the invest to execute focused to term long initiatives call on we in we over growth As to

Wayde McMillan

Thank you Shacey.

terrific we our during and a noted, operational no year, performance financial XXXX quarter consistently Shacey fourth As was had the exception. and outperformed

value are We will with our investing a our our improve further and continued lives on strategic growth additional stakeholders of for for execution mission of that with to people imperatives focus confident create diabetes. the

United XX% our end our to XX% of product was quarter high Omnipod range. of fourth $XXX.X $X quarterly U.S. delivered we consecutive By guidance million our $X growth accelerating of growth fifth range the $XXX.X representing above the above quarter million revenue the marked which million almost of XXXX, line guidance million in In States. and grew revenue of

with This product our channel. by volume contributing driven Also our mix of through benefit innovation was growing for pharmacy DASH. primarily the was the base, premium DASH Omnipod and on adoption from increased mainly new the increased Omnipod customer

Omnipod the DASH the U.S. users Type Omnipod XX% is new our channel growth of growth fourth in driving U.S. Volume on volume our to of through XX% our diabetes We focus of drove users quarter. our grew of the the Also approximately U.S. market. our to Omnipod total. X pharmacy over strategic

our $X $X resulting full million from of a PDM million realized strength and to into the of of year, direct headwind $X to compared continued For guidance selling DME we our the million PDM’s channels.

our as high driven As in our removes innovative XX% cost primarily Omnipod DASH in revenue drive eliminates hurdles in end less Europe, volume to negative as the to in new Pod we fourth markets adopting a guidance. existing for of demand for guidance our million, by model range, upfront the the $XX.X as PDM exchange increased reminder, from foreign achieving International headwind the grew quarter business therapy. assumed continue of a and well

range exceeding result high guidance basis. $X Omnipod XX% Drug a negative the revenue our quarter, Excluding revenue updated by an constant of the currency million, X% FX delivery partners impact in of $XX.X of as international end a X% the our was grew million, on increase forecast.

margin, QX, the Omnipod slightly gross of costs points pharmacy and down these manufacturing points as in volume in sequentially. year-over-year from was QX in Partially primarily basis DASH mix, U.S. ended gross XXX offsetting margin the XX channel. favorable to headwinds through XX% delivered than increased U.S. basis QX we were below Turning planned. higher QX

We in of to expect U.S. continue the headwinds manufacturing ramp XXXX.

As Shacey that over are investment will in meaningful contribute our margin innovation to short term the headwinds, noted, these term. we expansion long manufacturing despite gross confident

full expectations. was points of prior XXXX, basis year year, XX For margin the gross line XX.X% with in our below

the the direct impacted U.S. year, line pharmacy in offset Omnipod the well operations by for our U.S. from mix the first ramp manufacturing benefit Full Europe. half of in the the by during DASH of as year in gross year partially the premium benefit and was margin the from as the first

with the our $XX.X to X.X% expenses high basis, in revenue guidance for was revenue of year million of prior Operating income Operating the operating in On was income quarter our XX% quarter million of the in line or X.X% expectations. fourth were the full range. of compared revenue. exceeding fourth year $XX a representing slightly end XX%

convertible slightly extinguishment. income Net of the $X a charge original quarter and to remaining than of million for of $X million of the our million XXXX of the notes. XX% due the the onetime estimate included $X.X This relating was fourth better was the extinguishment to non-cash timing charge

quarter repurchase million of cash was last end We compared year of to at million $XXX from sequential and and $XXX the we remaining with in million $XXX XXXX notes. the ended year. This end investments the primarily the million decrease use $XXX at the the third to QX due to

We year ended with I global operational long will you over continued commercial and growth, growth XXXX solid through us revenue foundation, our positioning beginning term. the for expectations, walk XXXX and accelerated full guidance. profitability, a with improved now

including with growth approximate of an we to expect total of for revenue XX% for For revenue the XX% in year, total full foreign currency both XX% in and XX% impact. reported range negative the the reported growth range Omnipod company to X%

XX%. X X XX% reflects of Omnipod revenue continued and growth line, the expect product markets, of as continued Type access. Omnipod By expanding channel This in and primarily market to Omnipod U.S. volume DASH as in adoption pharmacy Type well we

no also will the premium for pay-as-you-go the pharmacy continue to strategy We PDM’s DASH provide from benefit to as of part charge. in pod the

full of quarter pharmacy. began of last DASH first start first Omnipod our into revenue As quarter. rate benefit move annualizing the DASH at DASH second growth generating of and at for the of from half year Omnipod end a year first the XXXX will launched reminder, Therefore the we and the the

as of be growth in the first we stronger rates a result, As than XXXX the anniversary our in launch. the half DASH to we second half expect

year international full X% currency Omnipod growth in continued approximate in of revenue rate range This to XX% markets. expect existing XX% reflecting the XXXX We negative strength impact. our an foreign includes

to XXXX As a expand new these over countries to revenue don't expansion Europe previously new to foundation although revenue, East, materially we laying we expect into strong Middle mentioned, we markets term. long and are for plan the the within and contribute

based partner’s Lastly XX% forecast. we our a delivery, expect XX% current for of to on decline drug

first an volume total XX% to impact. quarter growth For total growth company revenue to This of with XX% primarily both expect by growth driven X% negative approximate is of globally. XXXX, the and of increased currency foreign including XX% we XX% Omnipod Omnipod

growth XX% Omnipod QX, U.S. includes This on revenue of prior XX% to include year versus did not Omnipod which DASH.

drive Type Type first diabetes the reflects we X access growth market as within and quarter expand to Our growing and Omnipod X markets. both volume continue

negative This primarily we partner’s drive existing impact. delivery We expect volume penetration to Omnipod as And by decline lastly, increased upon our continue our growth we an XX% current expect a of drug X% international is markets. XX% to based including XX% revenue in growth, forecast. revenue growth of XX% currency driven foreign to approximate in

basis. rest turning the P&L of on Now to the year XXXX a full

We expect with full year. consistent year be relatively to gross the margin prior

expect continue manufacturing additional, term as our efficiency. As we headwinds operational previously ramp short and communicated, to we gross automated margin XXXX, lines in we highly two move toward experience to

As a capacity to each May reach everyday. We line. up our first we're years making two line typically progress year, last and installed of full reminder, to it takes on in

on to term begin our the to headwind. by continue solar also expect contributing short to second manufacturing of We production mid-year, product line

XXXX target U.S. grow gross that confident we volumes, efficiencies, these and we margin achieve XXXX to short margin gross over the and of expect half. will our half we we manufacturing ramp are we As headwinds, continue to gain second as of term Despite XX%. first optimize improve

our entails. XXXX, in strategy Overall financial

of therefore range. XXXX our expect capacity and Omnipod redundancy in EBITDA in clinical in efficiencies. including and of U.S. full and deliver initiatives expansion We year adjusted percentage mid-teens commercial manufacturing launch, the to our cost ramp pipeline innovation our our expansion, for trial Continued lines anticipated investment the Horizon investment globally,

capital expect with we our in and relatively as to global expenditures growth continue profitability and our in to to invest innovation we expand operations, U.S. capacity Finally, build support consistent XXXX our be infrastructure, objectives.

In summary, further XXXX will and our from XXXX terrific a strategy. as the we execute was year, benefit momentum

to expand continue the we forward Omnipod both We for and innovation commercial, to Horizon. Omnipod across it new launch growth, of U.S. DASH look invest and to Canada, will and watch in Europe countries,

execute on mid-teens. in objectives, of the solidly in $X remain margin XXXX a and deliver strategic income gross make to of impact billion continue lives We on on our and targets XX% the We customers. to operating positive revenue, track of our our

to for remarks. concluding turn that the back call Shacey With I'll

Shacey Petrovic

Thanks Wayde. our was strategic significant tremendous made as a Insulet XXXX year progress for on we initiatives.

are We impact from strategy the is entered XXXX position hard team, It the positive strength. and work now Insulet to efforts. beginning a sound realize the that thanks these we to of have in and dedication clear of we entire a

turn now Lauren Thank you. call I'll for back And the to Q&A.

Operator

Thank you. Our Matthew [Operator first Piper question Instructions] Sandler. with from is O'Brien

is line Your open.

Matthew O'Brien

Hi, for my afternoon. taking Thanks questions.

on is of bit has just here, QX bigger a QX far guide? but the base starters your that bit I a the or for as guess talk your guide attrition is last there pharmacy we've the you a conservatism? I through of sequential going could thought drop revenue Just that – more couple U.S. maybe is little about and Is years, that guess bit, little the number surprised a bigger, just in process some is than you note goes there, anything over of that's as seen etcetera

Wayde McMillan

Wayde. Matt. It’s Hi,

call all for thanks the of and question. first the So for

here. second from guide is half I in pharmacy, There time tougher our a For referenced for a give for the XX%, and couple half. for benefits key to were in confidence mentioned a strong year, us also drivers that a that you feel the guide. to that QX the create XX% of first U.S. strong XX% XX% DASH we the guidance, does that us

here the QX So the we above full have year. guide

positioned starts larger patient We there. XX% percentage, have you of we're a or in from know QX coming our X well new and Type very

XX%. that of XX% in lot a confident So reasons the to we're

XXXX, potential AID competitive the one create some new will marketplace. so aware do it in in in we and of are now second the a marketplace out We noise think there

QX. in We haven't that seen

why so in we're And guide. confident this that's

of is strong part a comfortable So yes, guide for I we that is this us, the U.S. XX% a just guidance in standard to a your guide. think question the second that to practice and feel XX%

Matthew O'Brien

you and companies a I say that, so one bit your fair. heard that you the think to And phone, when the link have then talk pivotal? Horizon products in Can the That's AID for their Okay. I of call they on flipping exactly to Horizon of one yes, track over little don't their specifically, of mentioned in on second, because Thank did the for and we're enrollment timeframe, a you. yesterday those finish you then a specifically. about delay

Shacey Petrovic

the on question. all this Matt. trial the We track launch Yes, end system. at for the got year. remain for Thanks on of participants We've XXX

now, way we're learning XX% and you as right imagine. the So about a might ton trial through the of

give So and new team great seeing you our with country these a kind just It doing and progress within job collecting little do is and trials enrolment? more typical learnings send users we home across for enrolment. of supporting so why opening when the good was exactly addressing like we're And when sites system do first that's you But you there. a like things certain finish bit making weeks of obviously, the the this this, time. to there, a color would see

on. don't been pretty exact very participants So And incredible. the Demand and early has know emotional But frankly I was feedback from trial the date. gratifying.

working consumer address is it's very we're the get really no in trial to to hard But as demand our that as possible. nothing So system timeline. quickly from high the changed and and learnings market doubt collect,

Operator

you. Thank

from Our Robbie with question comes JPMorgan. Marcus next

Your line now is open.

Robbie Marcus

some How quarter the installed first in in a second revenue as go of strong I and with we more guidance on a pharmacy your the after Thanks. base have drivers a is are there getting the such as really patients year seems some for business. recurring revenue to benefits Wanting away upgrades. the more it But the it's the and growth that'll realize should in recurring do mix thinking Because decline XXXX. And maybe about follow-up Wayde. that guidance, and U.S. mix number? sharp such What's Thanks. you premium growth guidance the strong in for just price the of volume? price such be business assumed half like there you're

Wayde McMillan

Hi Robbie. Yes.

little to guidance, So here perspective the close had for the we to with the it in strong particular to a XXXX, a growth think us year-over-year yes, I U.S. which your can the One more try that to we same way question. half. that growth dollars similar to is have in DASH in add very with year ramping the was second pharmacy in about earnest

And benefit so, the quarters into the for second for moves DASH the annualizing XXXX in we see the do moving pharmacy. and launching of couple strategic of

Horizon does impact XXXX. it material ramps XXXX until in revenue not to have a in

similar them dollar see had coming going many with we're half and the to of that momentum keep strong here We'll to that XXXX the we there going and in feel the marketplace and in the year dynamics start we're as monitor into tabs we So the the year. throughout monitoring. how we first to right on growth XXXX is we're those year here level progress

Robbie Marcus

any I'm sorry manufacturing safety from any across prepared in a disruptions you touch you potential calls supply you touched can Thanks. on is? impact jumping chain of How But different coronavirus? I'm tonight. here? you couple stock and Okay. supply China much your in foresee in How on China this remarks. And the if have? And if

Shacey Petrovic

because we I are first a not incredibly anticipate managing team Yes our to do Robbie. they time. supply the just through great commend And due coronavirus It's product any capably at issues to want and this question. this

As we bring Shenzhen. one and the risk we ground then and best and two got starting we've on on line in the frankly mentioned redundancy capacity provide U.S. to our as and line additional earlier here manufacturing our in medication automated And is this ramps on. people facility

a to we've place plan sure that make mitigation. got have comprehensive We in risk

producing inventory And facility more then on up is continues again. acting more day. our hand. also in Shenzhen And So to and then every and produce plenty of

it right putting we in we're think the that now a I and mitigation we plans as solid if closely sure incredibly So managing every feel position in proactively making team are monitoring day this is place. and

Operator

Thank you.

next Morgan Lewis of Stanley. from comes David Our question

is open. line Your

David Lewis

Good guidance Said I'm just few afternoon. U.S. about first in Thank you. your about quarter. than guess XX surprised rate the growth I in by faster the very of very the is to XXXX growth a because simply, the points Wayde, clear you of questions fourth I be quarter guess rate here.

what really your business. the is stable So you're reflects saying guidance in momentum

You just comps half anniversary the year? to back in harder going of the

Wayde McMillan

correct That's

David Lewis

And Very the of Thank was just Okay. into bit a year. ex-U.S. Ex-U.S. business the half little slowed back clear. momentum you.

is for half dynamics Your with walk last actually of guidance I consistent Can sort for question said XXXX XXXX the very in Shacey. you just confidence what and us you ex-U.S. back quick of guidance? over months. the couple your through XXXX then And a had

Wayde McMillan

for been range that said We international high-teens, that's XXs. you the as outside Exactly, long our continue to can grow here low we U.S. guidance has feel stated David. that the Hey, in

where guidance in we our so is to FX that XX% the OUS And region be. is range right right to guidance XX% and expect

better or for focus better shorter the pipeline strong We have typically international. have quarters. a insight the into in also We guide QX

taken XX%. that That's XX%, FX the we've on above And XXs range basis so ex to up to high-teens an year. start low the

overall, But by therefore We well distributors through in have region. to that for as regions now most there, potential still uncertainty for going business high-teens, in stronger think just low I to is pipeline. But think we where a this should the XXs the to be. business insight guiding overall, to for attrition. the We year handle sell on we've our good Europe, have little direct a we're we as expect account we some by us annualized and some going start to

David Lewis

last Shacey, the happened Thanks gone couple XX% last [ph]. is, one then, TX quarters months. long remarkable year momentum. that's over that's to to Okay. the question things can XX% has XX% so from It's been inflexmen six And this term? guess basically much. this pretty of I just just go or the Where that

Shacey Petrovic

question. a David, great it's Sure.

I X, a about wood early I think business days think and our launching in into I new think there's product a it's Europe. and about to lot being only a Type of in still chop year pharmacy,

to go. So, Type caution into it want I for just can think But context and where put I X I -- us. guess where an I incredibly that exciting opportunity is

dose believe good of that have twice specific United least population. X results patient we've incredibly data outcomes just and size there. users opportunity. in of access Type total clinicians anecdotally of large opportunity reduction great obviously the the the And we're an daily got from other We States. around both at in We it's insulin and seeing It's and

So, technology we lot scratching in frankly and think tool have getting tools. a clinicians is just that a great who And this don't patient surface people to runway the we've DASH segment. and where underserved and a just in great patient of market long are got a that this providing this population started we're

invest going really We're think while. a the potential to I So excited the it's with to hang and to unlock about to us we're continue for going opportunity.

Operator

you. Thank

question next Our comes Baird. Johnson from Jeff with

is line Your open.

Jeff Johnson

I on insulins to follow-up questions. ask maybe afternoon good the concentrated One, two guys. maybe you just sideline here. Shacey, want to decision Thank you the

really data so I'd of I with it's just issue insulins. seems is the turned efforts. insulin up there's or delivery issue? other concentrated of bandwidth kind like of down itself, Horizon, You've couple coming want side, much And itself not over concentrated stuff more a sure drug there's on bandwidth? on the assume that to And It next? some the the would of what imply now the make What taking going product next a an is years. That of lot of on the beyond

Shacey Petrovic

tough make itself to an It about having a not choices leadership the Right. data essentially as have the Jeff, itself. is we that to that's issue true. product make. team the This or is with

great to the and more to be about Abbott, are combined of the quickly attractive and can insulins programs is in And most is both market us we terms sensor, job into potential ones to DexCom's position opportunities use we the we decisions those opportunities. that the growth now think And with addition Libre that have we of those and value right I drive of we opportunities multiple them and can in our think to going organization. the next have tough that in front for steps how prioritize the drive to thing the and those believe generation market size. make the that take potential are

bring insulins We diminish attractive It our with terms lot really a means of have concentrated opportunity. value pipeline. powered public enthusiasm. thing both at we platform believe pipeline opportunities. doesn't have Type entire living continue diabetes. we that on more as X look that going that haven't here. with been people X we and a It can just one grow Omnipod attractive an There's and Type But Horizon to is evolve to our And is and in said by the we

to plans marketplace. that into of to exciting really continue front got the on we've so And bring platform that iterations

think one right I this of we driven And the evaluate other. of so versus all is decision. number the It's by that analysis program do kind a to

right prioritization prioritization. I think the and is did team evaluation a rigorous the level this

Jeff Johnson

the horizon on maybe then a just question pivotal. And Understood.

May-ish sure a some little I we study. started, bit. could at enrolled So if chance it three-month a wasn't just let's least like seeing or at see kind or weeks January mean Is it also really do the FDA you to a think few year? data to this to by data. summer said it sounded Thank get was three together. of after I approval data the that me could the months fully any by month at pivotal you push say closed complete, late end you. the of if at this we're the deeper pivotal comments, into be but see checking we second going know crazy if sometime it's half ADA. the we seem it data. mean so it And of It pivotal I then or least completion to pre-pivotal, a from on there study wouldn't primary your of

Shacey Petrovic

they for and with on people to the Jeff, sound get be actually as enrolled able then it to on time. in so need the and But enrolled completely to trial participants put They're say seen and like I'll participate that Yes. the then right. a be takes some while -- we you say product, me team. takes trial the to when product

it happen So overnight. doesn't

we've have patient-wearing under trial days X,XXX days about this pivotal collected about course from got XX,XXX of over the the and belt. expect We patient-wearing to our

time to So go. got we've still some

in of hesitant timeline. lot a I aggressive that kind I'm process. so to more learn provide And think to a

said later think to I right this work the what that that we've feels as on all and year me. Based happen. needs still to

final data, to stuff we are I learnings us about take think to to -- commercial about some move data, we still learning that think, every how cautious with do to this. has forward react time I day All we about happen. want Because we determine for the the just before excited it's that incorporate guide collect be program. think any product. want that going to I and the But to I

So committed. We've it's product. a think people be, got on teams And going are I it. great to terrific

Operator

you. Thank

comes Blicker Our with Ryan from next Cowen. question

open. is line Your

Ryan Blicker

And the then, expecting U.S. about U.S. stocking couple base you follow I up. assume What Thank pharmacy Hi. on with you then U.S. base the posted for occur U.S. was versus the U.S. channel my And installed guidance any in taking on the talked future. to installed growth what a in revenue. the for associated growth revenue you A And XX% QX does in move have questions. in stocking some XXXX? growth XXXX? Did QX? call in

Wayde McMillan

Ryan, Wayde. Hi, it's

patient base So, us. quarter record new it Shacey's we're at that quantifying said what providing prepared we not start was time. installed But in for another this remarks

So before QX our added installed quarter that. had more in any base than we customers to we in

about stocking, again see we all stocking we regarding And that's then say QX. in not So on did QX can this at that point.

channel of build did our is it side So the by channel reductions net And DME what it's the some pharmacy we on pharmacy different about that the which very was on learning see a side, but we're offset is efficient. business, channel.

basis did a QX see on in not the any channel for U.S., we build. So net

expect pharmacy add more and channel distribution distributors end see think we we We the partners would build to to said to happen. did channel. DME to DME on at more point, of pharmacy our we the eventually when a settle then do Having inventory side. business not And when start of on will can't that the in into that's some the we to we're we think wholesalers guidance time the and that, do that time because channel going we we channel see add it over there. our channel some build -- offset add and out we build continue here, the once the side However, we're efficient channel the retail by that in we we this not start learning. It's reflecting very a

for certainly build, we channel So, it see call of a up you. we'll material amount inventory

Ryan Blicker

Got it.

difference Okay. amongst is as U.S. X.X million companies to patients, about you two base? bit the you X in Thank questions million seen have bit Can above talked addressable about. attrition And you which it? got Type what how confidence and estimate a to installed a overall talk been market users X X other in your And you. total Type notable X then any your or Type versus following you've Have the utilization that

Shacey Petrovic

when attrition first or question And there's I'm isn't tick X Type haven't to X. what population. user with which isn't noted We've But to referring a different. of a the lot conclusively up. I Sure. early was notable in of utilization I'll different habits. say attrition start seen kind or a with It's say utilization with just still Type to. it's a that's utilization chop the change change early wood But we in the days little

So monitoring seen notable regarding And difference. carefully. those the date we estimates. we're to question a And certainly haven't then trends the

will number in So based access. pretty remember research that solid And be bunch market of has the Type might reports, access IDF comes from data. -- X the Atlas we a on difference on And one internal organizations that haircut triangulate external Omnipod population. and sometimes other

And the other companies so that same have don't might. we necessarily haircut

Operator

you. Thank

Our with comes Jayson next from Raymond James. question Bedford

Your line is open. now

Jayson Bedford

Good Hi. afternoon.

the follow-up comments What context X as new fourth Type couple around your to your a X a the semi mix base? Just percent the questions. is users in Appreciate in installed Type quarter. the of current

Shacey Petrovic

So, did Type catch that X… I Jayson. didn't When the

Jayson Bedford

the… of The mix

Shacey Petrovic

overall I Oh, mix. see

of get to last we number it base. XX% updated The number haven't was an XX% gave We total there. it that the was that

Jayson Bedford

Maybe for Okay. Wayde.

On business your guide mentioned the to-date. system hasn't But U.S. your the you impacted the to did U.S. mention business. AID in reference device you new

four? contemplate the two the I impact is, does through guess So, more a question in quarters competitive guidance

Wayde McMillan

there a monitor that things potential So and for hey, -- Jayson. marketplace. To now and do see we in our start maybe with, out And we one second. recognize there's

Having our Omnipod for we part. on just to given said that new pump how rely So renewal our come was comment customers looking my XX% guidance two that at MDI, market factors is from most the there. the that, out don't get really cycles of we

create factored said we to noise And it piece it a some of into our that U.S. we're so, going do in having and to think will haven't closely. the monitor guidance impact range. that, market we But major

Operator

Thank you.

SVP Danielle Antalffy next comes from with Our Leerink. question

line Your open. is

Danielle Antalffy.

for a Thanks strong really much question. guys. so afternoon, Congrats Good taking XXXX. the on Hi.

every in onion the basis, Sorry But tougher. the that Because a to peel accelerate. to really And continuing appreciate to adjusted U.S. is like XXXX bit we momentum in back i.e. I on a mean, just the even actually guidance. quarter going just direction other the harp comp could. you wanted on the little if growth. But I accelerated comps get you're in revenue feels more it

I'm the So it not sort more as I your just or just relates want something missing conservatism this of to on is to sure make prudent part guidance?

Wayde McMillan

Yes.

Wayde. it's Danielle, hey So,

dollar to What like not So factors. there's bottoms from And a our assumptions. up topic quarter. popular growth new to dollar our We had to quarters. us for do growth Again, going to do record going in give we're the to quarter-on-quarter of here. build in brings the factor context is we rate. this close and sounds out quarter, ordinary patients growth XX% approach. start take for that external XXXX an four thoughtful we internal every guidance growth standpoint, the U.S. a a We're nothing a include it the We thoughtful to I did XX% this that is approach here. take factors, is

in a the We strength first is that strong guide the quarters. for see feel we some year. So

and feel continue we and as above that it where assess is goes So we're along. comfortable to guide year very QX our the we'll at,

Danielle Antalffy.

your Horizon, I want mouth. But Okay. really is to nothing all we assume then as I I in mean don't Totally -- fair. first in words about And put think of the assume more adds nothing have? new accelerating patient XXXX you see or really current like the guide. a sustaining launch growth you the product just is in momentum Is as that that

Wayde McMillan

Yes.

advantages on it we're XXXX year. Horizon the So will product the have to not deliver an the think Once this ways and point. for guidance excited We in guide have of planning going to a and second going we're to material revenue. of the XXXX proposition give then system. about time. we're that, to this at we that our technology do value do not patients brings yet. very on impact the update it We're not ability to broader half more that to we'll launch to But of business the at Horizon in because any the said it provide Having what will

Operator

you. Thank

Blair. William with Kaczor Margaret from comes question next Our

Your line is open.

Unidentified Analyst

because we actually adoption it's to just how This within in focus under and are Type Hi. where the rather than on focusing kind relatively heard the go. patient Thanks penetrated questions. we to taking can of pretty impressive where Margaret. market for Kind it X for now. of kind the focused population Brandon of got you've is again on wanted I on

been in of And had MDI the -- in been Thanks. Or Type guys insulate then Type -- X also it's on kind X of is a push patient you XX% to of patients are plus pull? interested they follow-up. Type And kind more this have more So or a of your I converts? coming own? are X patients a into has out marketing population? actively been finding Just their

Shacey Petrovic

Great. questions. Bran, good

in pull Type over Insulet of the with with up a terms of securing would as people of set Medicare remember foundation living age that X strong describe are got XX. it I really. strategy it because reimbursement, a So, And XX%

this like drive And seeing really has the It then to reducing burden the cost of And upfront so that otherwise of this would business think it for Omnipod and for to and eliminating the patient. among tried and helped the also model risk the Medicare cost predictable And reduces to sticking be a for payor reimbursement patient give able physician to more just have the not I is try we're population in important then the order adoption population. who it people it it. actually and obviously to cost encourage with more they are go. makes users

helpful of particularly are And this in patient really those so things population. all

then in design for think the Type I DASH And particular are some appealing has also very X that segment. features

living our it launch new before educated And have benefits. to so Type sales teams then clinicians to be tools help And we they programs Omnipod and X to able with potential provided obviously help users speak. resources and so them diabetes educate with and on buy potentially try these them to it,

think that who adoption. can helpful especially successful for going growing seeing drive user continue. among clinicians that's these for all been think aren't experience they tool a I confidence we will the as those away. things helping in is base these I really why have have wheel, that increase us are that's that patients So trend And of and Those this the

Unidentified Analyst

the of But pivotal week. year. what last at saw -- from we Got coming in then U.S. I Tidepool you the was Thanks. interestingly end the it. That's some study helpful. on data have Horizon ongoing their And saw good pretty

how the guess baked any that is want And on approved a So, your to two, question for system? if once you approved. that say, the Omnipod I Is I Thanks. long of enabled that when with kind being be into you there appreciate market one, might take guidance? that Tidepool now? won't of to today, be gets numbers approved it in would theoretically was approved, it contemplation comment let's then on But is so

Wayde McMillan

Sure.

So guide, the like. if I can you with start

in including the for yet, our on are that market So products not we're not guidance.

-- what So that's to impact our if Tidepool the the It's easy they front. really up time or product it line assess any and we'll when when not. is and it when launch to has answer their guidance an is on them

Shacey Petrovic

around the we've with what started to look Tidepool might like. discussions have And just commercial launch strategy

release our ensure to market know that to limited is for tested it's what something speak important say I highly, really particular because would for is. fully tested We I fully a system. we unanswered and if for strategy their in of and We to questions lot that will Tidepool we strong. capabilities. will Horizon I Tidepool support require highly want there's think going encourage the don't terms so have is not internal do, demand a that I that be of in Horizon for that

performance, that sure And of that of we so, of all we want product like sound terms a training, to in support get the that. launching surround make right

go the of means I a we we'll be So, full a very won't clearance. a release market a which and of typical for into limited release kind think after see will it execution probably months that, market

Operator

you. Thank

question next with Our Raj Jefferies. from comes Denhoy

line is Your open.

Unidentified Analyst

Raj. Apologies. for Anthony

Just a on Horizon. couple

Just a Libre X.X. delayed for that Abbott wondering, on actually What the bit. timing the side and is that's been certainly

FDA to So to X.X? the just benchmark in Horizon the I'm just And from we And for up follow-up timeline with put horizon the on insulin Maybe target wondering views viewpoint, is was for? compares what clinical just be again. would that how on range Thanks looking trials? DASH what's then think the Libre integrating time clinicals. the and

Shacey Petrovic

Sure.

when on working just significant and we which finalized programs them. these then Libre, with the start agreements. funded I'll happens that's resources once And So, that become start

submissions for the launches. will and So regulatory together work program to then teams define those and timelines then

don't we and it's But strategy their Libre. timeline. comment come guidance very so alignment on for in And partner. Abbott our and with -- we'll all clearance that We're finalized our wouldn't partners. and out as confident to communicate their iCGM that I is

dependent iCGM So is Libre in program Horizon upon our regulatory clearance.

and was second Horizon then And the time question on range.

we about blinded I think the clinical we're to data pivotal feel date. have data. -- very excited to And -- but published the we're not that we

we publish won't data it. timing coming of out don't present the investigators the we have and/or have range pivotal. So We our visibility to until that

insulin time and FDA, that delivery as of range these or the -- opposed for range a target. by haven't manage iCGM would with -- I about really So I It there. and particular validate they manage special for And for lot range and effectively has patient controls. the have glucose iPump CGM how there have those delivery special part I a to setting timing insight of a particular just focused don't discussions really the for aren't iController, really In guess our to as out targets been been and systems safely controls on for pointing now and which time published target.

Operator

you. Thank

Our Matt next question from comes with Taylor UBS.

line Your open. is

Matt Taylor

I for Hi. question. hoping the taking was you broader on guess, forecast assumptions here. I some you Thank would the might expand that impact your of

similar see So that market assuming patients. conversions the are of you for we

We have pump patients on number? therapy into strong to or get share of can that to forecast? things anything guidance imputed that you the you ASPs pretty in to And conversions other MDI this

Wayde McMillan

near dollars, of in in having investments teams U.S. the from about both lower DASH lot We're excuse we be play. details going providing that the the go But still the of will U.S. in into finery a the not growth dollars outside we've that me, did range that, in it benefited had details. be on than level the I Matt. we made pharmacy end high Hey think the growth up What guidance XXXX. range we if not in forecast. was We're bring. end XXXX to achieve share a are But also near will Talked guidance that in in if lower the dynamics and and we that, we that XXXX. said the the commercial Obviously we benefits those our the

things. gain and We experience continue commercial side to of strengthen on the

reasons what think why type we're lot this XXs of momentum. further year. a at this can lot get of rate growth time. high-teens, a to down We're low that's guiding a I for drive believe and not got to business the So, we've on of got into for to continue to a we details We've going that

Matt Taylor

Why Okay. going into But Maybe your growth assume these than forecast? that or getting international, being markets doesn't that new you're aren't into doing these with you've some revenue high-teens a out about just conservative new Previously pretty markets. rate markets. you're you that. the any of going baseline of lot you're you better as talked on growth

Wayde McMillan

Yes.

different establishing getting lot of actually, we're growth had Matt. business to in low strong in a rate. particular to high-teens, make support growing high-teens, XXs the markets, is significant a very and a XXs argue responsibility taking Europe low and investments countries would rate a I growth to in out order So build multiple We the ourselves infrastructure across in Europe. over And

high-teens, low that So, at pace XXs strong a we're we a think rate. going at growth

get It a accrue into five countries mentioned material into that customers in new lot talked model year. moving we going the five new of time revenue of our countries beginning, period from about of and takes a we've really to of You enough and the to to it the because level when the don't countries to a new get these strength business revenue. speaks annuity this we're

once the acquire think about for So durability enough model, the revenue I stream the annuity thinking us, customers. we of

period on. smaller. And them in it's for so markets less is of But people to and a these for of total the you get Europe us very takes in because When bring it a large have than to all available more little some people Europe market. market time dispersed, bit us it's a aggregate these it for countries these

of we're happening in Europe. And keep happy continue with to to low to So going rate. growth make actually the the that investments growth XXs pace obviously we're quite high-teens,

Operator

you. Thank

with next Lichtman Our Oppenheimer comes Co. question & Steven from

line open. Your is

Steven Lichtman

Wayde, be you Thanks. I end EBITDA non-cash guide? XXXX the and of XXXX we what should Hi if or level missed questions. Maybe in apologize assuming EBITDA financial set guys. just margin? this. a to on EBITDA expenses guidance on And much the Where up just I couple how did

Wayde McMillan

Steven. Thanks Sure.

clarify, Just EBITDA. to adjusted it's

finished So XXXX. in we low-teens in XX%

so over for is guide a And this our XXXX. improvement slight year

Steven Lichtman

guys. overall investment it. Okay. force about And will operating growth some be Got in be should sales How XXXX. just in thinking you we in then growth And XXXX? making expense core

Wayde McMillan

Yes.

making into. the be line about the as pipeline number our you in investments the invest investments our majority talked not levels commercial continued year be for means in which as in for R&D expect outside continuing in continue new and the we'll to about that And our there. making talked to what can the to well U.S. several the us throughout times growth in that is invest of and and growth. and selling operating is one, and is, outside we've But will marketing innovation -- at we sales strategy particularly both that are for expenses. what specific force U.S. countries moving We're item We guidance U.S. providing

still But than more the pace to continue that can we the We R&D functions leverage in support business are the we of off assume you it's investing G&A and because when have off I marketing. and selling to support the order at growing are. build think G&A in to

Operator

time Thank last question. for one have you. And we do

question Kyle comes from with Canaccord. final Rose Our

Your open. line is

Kyle Rose

a little are the wondered Thank of we you that your very MDI if bit starts you of guys fact the me take think new Great. ask I coming a different and from could just much for a squeezing step a because just patients inside. gives about question back broader market, XX% perspective. I

just market I then market? as perspective? that that could do how wondered how Type about maybe think do -- view a market share Type a do think how if standpoint? you is And Type do understand you within pump you from just from So from X from you us penetration big help perspective X a X a think As your well that

Shacey Petrovic

of best the are of from diabetes the penetration XX% that that in data has estimate the growing. there been living with -- terms We that pump approximately Type U.S. Sure. have therapy X using is is don't pump and people so we

really XX%, don't our opportunity percentage We at you people pump living estimate insulin note therapy. are than XX% ago. just to daily years contemplate multiple of X We relying And We much total more of as of Type because point with from X diabetes from dependent less injections. XX% but of percentage than come up users market. XX% recently on that's of pump couple the think XX% So our more the is about that. our usually a X% smaller Type this probably

a market head really in terms share. my have I the of off estimate top So of don't

Although Type have I share has probably occurred. in growth would say, just way largest the market we the given X the that

Kyle Rose

some DASH. launching on a I channel. also mean, obviously that's happened. the way up one question or that a Great. And patients it dynamics -- know, of using a implies the for you're of talked that I of percentage up component about the But some pretty you just pharmacy when then to you as on follow lever DASH, talk as about initially pharmacy the the it patients DASH, patients there. percentage DME of penetration when coming healthy to open was the versus getting

could how if just as on some with channel. the of and in on you're in the barely using And lever a on wondered widen channel? So just I DME regarding that DASH conversations Horizon plan availability payors having your the one, you to you comment the pharmacy maybe then contracting

Shacey Petrovic

Sure. Horizon Those and are great all time channel. about the leveraging talking terms questions and pharmacy of the in we're things

DASH channel. have model. in the have one to really contract through pharmacy the available We pay-as-you-go today, do that's they where And distinction. channel, the is so DME agreed the primarily pharmacy And

the that whether in in, payor an grow attrition. and one agreed a this are pod. DME what we in should do the call that attractive whether they or side, for the our be So that helps upfront contracting value what in on frankly premium you're proposition pay-as-you-go this contract. to, among we X particularly have exchange we what DME to Type in in risk the And DME DME member it eliminating so is offset to large believe payor And model for the large helped actually or the side and a and cost, the risk is we we adoption segment channels, firmly model a open pharmacy for absorb because case, XXXX believe and but

might we grow, the beginning the and decline itself establish the progress we one year. So channel we such we that while of have the may way And may see to started at grow. that of see see and great channel surprises pharmacy, the that or in in DME that expected frankly, did started also to consequential the see was not XXXX in not

thriving. it's great So see both to channels

leverage we You want pharmacy but the work well is in in, grow across then this see what believe question the pay-as-you-go regarding we've have you is rather wholesaler that launch our done that the and DASH Horizon, technology model. to Horizon know of suited relationships our rapidly second pharmacy the regarding in. that so all intention with the particularly we in establish the particularly And partnerships, we to agreements, which preferred establishing pharmacy, all PDMs both what to potentially to channels, intention the pharmacy, establishing with for our of establishing can of payors these leverage channel pharmacy the that the in access and is the all is

of But channel, think which I rapid rapid in with it would it so to DASH XXXX. we points We're out, was did it point in access pretty do I we hoping DASH, to faster and that quickly the pretty Horizon, just nine strength in adoption months really with established proposition. the with but value

Operator

I questions the conference further you. to to this are Thank at no turn Shacey Petrovic. back There now time. would like

Shacey Petrovic

with Great. who to Thank and diabetes. you progress. everyone year great about Insulet team forward throughout exciting improve speaking to the XXXX people evening. another be Thanks, close tirelessly year of continued we global and thanking to you to Insulet I for lives for works joining going have with all of the our want look is our call today. our a by

Operator

this and a wonderful today's for concludes you gentlemen, Ladies conference. participation Thank your and day. have

You disconnect. may all

Insulet (PODD) 25 Feb 202019 Q4 Earnings call transcript